

8 December 2023

## Buy

<b>Ticker</b>	AET:AIM	
<b>Oil &amp; Gas</b>		
Shares in issue (m)	220.1	
Next results	FY Apr	
<b>Price</b>	32.5p	
Target price	54.0p	
Upside	66%	
<b>Market Cap</b>	£71.5m	
Net debt/(cash)	£4.9m	
Other EV adjustments	£0.0m	
Enterprise value	£76.5m	

<b>What's changed?</b>	<b>From</b>	<b>To</b>
Adjusted EPS	-0.8	-1.4
Target price	54.0	n/c

## Share price performance



%	1M	3M	12M
Actual	18.2	33.5	24.0

## Company description

E&P company with a 'buy and build' strategy focused on Africa where management has extensive experience

## Jonathan Wright

Director of Research  
jwright@cavendish.com  
020 7220 0543

Sales desk 020 7397 1930

Trading desk 020 7220 0533

\* denotes corporate client of Cavendish

## AFENTRA

## Sonangol deal completes

Afentra has completed the Sonangol acquisition, the second of its three Angolan deals. This leaves just the Azule Energy transaction to complete, which is now expected in Q1 2024 but should be a formality after today's positive news. These acquisitions deliver Afentra a material non-operated shallow water portfolio in an established and prolific hydrocarbon province containing significant production enhancement, development and exploration opportunities. The improved fiscal terms of the producing assets are now effective, and these highly free cash-generative assets provide a solid foundation for Afentra's wider African growth ambitions. We reiterate our Buy rating and 54p/share risked NAV-based price target.

- **Sonangol acquisition completes.** Afentra has completed the acquisition from Sonangol of a 14% non-operating interest in Block 3/05 and a 40% non-operating interest in Block 23, offshore Angola. On top of the earlier INA deal, this increases Afentra's interest in producing Block 3/05 to 18%, which will rise to 30% upon completion of the ongoing Azule acquisition. It also provides a 40% non-operated interest in Block 23, which offers long-term development upside potential. The expected completion of the Azule transaction has slipped into Q1 2024 (we assume 1 February) but should be viewed as a formality by investors now.

- **Net completion payment of just cUS\$10m.** Afentra paid Sonangol a cash consideration of US\$21.1m on completion, down from the initial US\$56.5m due to cash flow adjustments from the effective transaction date of 20 April 2022. Afentra also inherits crude oil stock worth cUS\$11.9m (pre-tax) at \$75/bbl, which is expected to be sold in Q1 2024, effectively reducing the net completion payment to cUS\$10m after tax. The upfront consideration was funded from existing debt facilities, with US\$33.6m now drawn on Afentra's US\$110m RBL facility following the INA and Sonangol transactions. The US\$9.1m previously drawn on its US\$30m working capital facility has already been repaid out of crude oil sale proceeds and year-end net debt is expected to be cUS\$20.7m, which is essentially wiped out by an anticipated year-end oil stock entitlement of c300,000bbls worth cUS\$22.5m (pre-tax) at US\$75/bbl.

- **Assets performing well.** Block 3/05 continues to perform well with gross production of 20,560bpd in November, up from 18,000bpd in H1 2023, benefiting from the well intervention activities underway on Block 3/05. FY23 production guidance of 19,100bpd is in-line with the June 2023 CPR forecast. Production uptime has improved from 77% in Q1 2023 to 87% in Q3 2023 with ongoing investment in infrastructure expected to further enhance reliability and uptime. Water injection rates are increasing, and a second phase of Light Well Interventions (LWI) is underway, with 30 planned over the next 18-months. The long-term production test at the Gazela field on Block 3/05A is continuing at 1,300bpd and will inform potential low-cost development options for this field via the existing nearby Block 3/05 facilities and infrastructure.

Key estimates		2020A	2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec	Dec
Revenue	\$m	0.0	0.0	0.0	15.0	114.7
Adj EBITDA	\$m	-2.0	-4.7	-8.7	1.0	56.6
Adj EBIT	\$m	-2.2	-5.0	-9.0	-1.7	37.8
Adj PBT	\$m	-1.9	-5.0	-9.1	-2.0	33.4
Adj EPS	c	-0.9	-2.3	-4.1	-1.4	12.1
DPS	c	0.0	0.0	0.0	0.0	0.0

## Key valuation metrics

EV/sales	x	n/m	n/m	n/m	6.4	0.8
EV/EBIT (adj)	x	-44.2	-19.3	-10.7	-55.9	2.5
P/E (adj)	x	-47.2	-18.0	-9.9	-29.4	3.4
Dividend yield	%	0.0%	0.0%	0.0%	0.0%	0.0%
Free cash yield	%	-2.5%	-5.2%	-7.6%	-20.7%	6.7%

## Sonangol deal completes

Income statement		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Sales	\$m	0.0	0.0	15.0	114.7
Gross profit	\$m	0.0	0.0	8.3	62.5
EBITDA (adjusted)	\$m	-4.7	-8.7	1.0	56.6
<b>EBIT (adjusted)</b>	<b>\$m</b>	<b>-5.0</b>	<b>-9.0</b>	<b>-1.7</b>	<b>37.8</b>
Associates/other	\$m	0.0	0.0	0.0	0.0
Net interest	\$m	-0.0	-0.1	-0.3	-4.4
<b>PBT (adjusted)</b>	<b>\$m</b>	<b>-5.0</b>	<b>-9.1</b>	<b>-2.0</b>	<b>33.4</b>
Total adjustments	\$m	0.0	0.0	0.0	0.0
PBT (stated)	\$m	-5.0	-9.1	-2.0	33.4
Tax charge	\$m	0.0	0.0	-1.0	-6.7
Minorities/Disc ops	\$m	0.0	0.0	0.0	0.0
Reported earnings	\$m	-5.0	-9.1	-3.1	26.6
<b>Adjusted earnings</b>	<b>\$m</b>	<b>-5.0</b>	<b>-9.1</b>	<b>-3.1</b>	<b>26.6</b>
Shares in issue (year end)	m	220.1	220.1	220.1	220.1
EPS (stated)	c	-2.3	-4.1	-1.4	12.1
<b>EPS (adjusted, fully diluted)</b>	<b>c</b>	<b>-2.3</b>	<b>-4.1</b>	<b>-1.4</b>	<b>12.1</b>
DPS	c	0.0	0.0	0.0	0.0

Cash flow		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
EBITDA	\$m	-4.7	-8.7	1.0	56.6
Net change in working capital	\$m	0.2	2.0	-15.1	-2.8
Other operating items	\$m				
<b>Cash flow from op. activities</b>	<b>\$m</b>	<b>-4.5</b>	<b>-6.7</b>	<b>-15.1</b>	<b>47.1</b>
Cash interest	\$m	0.0	0.0	-0.5	-4.6
Cash tax	\$m	0.0	0.0	0.0	0.0
Capex	\$m	-0.2	-0.2	-2.9	-36.4
Other items	\$m	0.0	0.0	0.0	0.0
<b>Free cash flow</b>	<b>\$m</b>	<b>-4.7</b>	<b>-6.9</b>	<b>-18.6</b>	<b>6.0</b>
Acquisitions / disposals	\$m	0.0	0.0	-32.7	-13.1
Dividends	\$m	0.0	0.0	0.0	0.0
Shares issued	\$m	0.0	0.0	0.0	0.0
Other	\$m	-0.3	-10.3	43.6	3.3
<b>Net change in cash flow</b>	<b>\$m</b>	<b>-5.0</b>	<b>-17.2</b>	<b>-7.7</b>	<b>-3.8</b>
Opening net cash (debt)	\$m	42.7	37.7	20.4	-21.0
<b>Closing net cash (debt)</b>	<b>\$m</b>	<b>37.7</b>	<b>20.4</b>	<b>-21.0</b>	<b>-28.0</b>

Balance sheet		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Tangible fixed assets	\$m	0.7	0.5	33.5	64.2
Goodwill & other intangibles	\$m	21.3	21.3	21.3	21.3
Other non current assets	\$m	0.0	0.0	0.0	0.0
Net working capital	\$m	-0.2	-2.3	12.7	12.7
Other assets	\$m	0.0	10.2	0.2	0.2
Other liabilities	\$m	-0.6	-0.4	-0.4	-0.4
Gross cash & cash equivs	\$m	37.7	20.4	12.6	8.9
<b>Capital employed</b>	<b>\$m</b>	<b>58.9</b>	<b>49.8</b>	<b>80.0</b>	<b>106.9</b>
Gross debt	\$m	0.0	0.0	33.6	36.9
Net pension liability	\$m	0.0	0.0	0.0	0.0
Shareholders equity	\$m	58.9	49.8	46.4	70.0
Minorities	\$m	0.0	0.0	0.0	0.0
<b>Capital employed</b>	<b>\$m</b>	<b>58.9</b>	<b>49.8</b>	<b>80.0</b>	<b>106.9</b>

Growth analysis		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Sales growth	%	n/m	n/m	n/m	667.5%
EBITDA growth	%	-139.4%	-84.1%	111.6%	n/m
EBIT growth	%	-129.2%	-80.1%	80.8%	n/m
PBT growth	%	-161.9%	-82.0%	77.8%	n/m
EPS growth	%	-161.9%	-82.0%	66.3%	971.3%
DPS growth	%	n/m	n/m	n/m	n/m

Profitability analysis		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Gross margin	%	n/m	n/m	55.3%	54.4%
EBITDA margin	%	n/m	n/m	6.8%	49.3%
EBIT margin	%	n/m	n/m	-11.5%	32.9%
PBT margin	%	n/m	n/m	-13.5%	29.1%
Net margin	%	n/m	n/m	-20.5%	23.2%

Valuation analysis		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
EV/EBITDA	x	-20.3	-11.0	94.9	1.7
EV/EBIT	x	-19.3	-10.7	-55.9	2.5
P/E	x	-18.0	-9.9	-29.4	3.4

Cash flow analysis		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Cash conv'n (op cash / EBITDA)	%	n/m	n/m	n/m	83.1%
Cash conv'n (FCF / EBITDA)	%	99.3%	78.5%	n/m	10.7%
U/lying FCF (capex = depn)	\$m	-4.7			
Cash quality (u/l FCF / adj earn)	%	95.0%			
Investment rate (capex / depn)	x	0.9	0.7	1.1	1.9
Interest cash cover	x	n/a	n/a	n/a	10.3
Dividend cash cover	x	n/a	n/a	n/a	n/m

Working capital analysis		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Net working capital / sales	%	n/m	n/m	85.2%	11.1%
Net working capital / sales	days	n/m	n/m	311	41
Inventory (days)	days	n/m	n/m	0	0
Receivables (days)	days	n/m	n/m	251	33
Payables (days)	days	n/m	n/m	n/a	n/a

Leverage analysis		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Net debt / equity	%	no debt	no debt	45.1%	40.0%
Net debt / EBITDA	x	n/a	n/a	20.7	0.5
Liabilities / capital employed	%	0.0%	0.0%	42.0%	34.5%

Capital efficiency & intrinsic value		2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec
Adjusted return on equity	%	-8.5%	-18.2%	-6.6%	38.0%
RoCE (EBIT basis, pre-tax)	%	-8.5%	-18.0%	-2.1%	35.3%
RoCE (u/lying FCF basis)	%	-8.1%			
NAV per share	c	26.8	22.6	21.1	31.8
NTA per share	c	17.1	12.9	11.4	22.1

## Valuation

Figure 1: Afentra net asset value

Net Asset Valuation	W.I. reserves mmboe	NPV/bbl US\$/boe	Unrisked NPV		Geological CoS	Commercial CoS	Dry hole cost US\$m	Risked NPV	
			US\$m	p/sh				US\$m	p/sh
Net cash / (debt)			-20.7	-7.5				-20.7	-7.5
G&A costs			-36.4	-13.2				-36.4	-13.2
Options			0.0	0.0				0.0	0.0
Angola acquisitions - initial consideration			-92.5	-33.6				-92.5	-33.6
NPV of contingent payments			-23.6	-8.6				-23.6	-8.6
Acquisitions CF completion adjustment			76.4	27.8				76.4	27.8
Angola Block 3/05 2P reserves	31.8	5.73	182.4	66.3	100%	100%		182.4	66.3
<b>Core asset value:</b>	<b>31.8</b>		<b>85.5</b>	<b>31.1</b>				<b>85.5</b>	<b>31.1</b>
<b>Contingent resource:</b>									
Angola Block 3/05 Impala South East infill	3.2	8.15	26.4	9.6	75%	100%	0.8	19.1	6.9
Angola Block 3/05 Impala infill	0.9	8.15	7.3	2.7	75%	100%	0.8	4.8	1.7
Angola Block 3/05 Palanca infill	1.3	8.15	10.8	3.9	75%	100%	0.8	7.3	2.7
Angola Block 3/05 Cobo workovers	0.3	8.15	2.7	1.0	75%	100%		2.0	0.7
Angola Block 3/05A 2C contingent resource	7.0	4.25	29.9	10.9	100%	75%		22.4	8.2
Angola Block 3/05 licence extension (2041 to 2045)	7.3	2.00	14.6	5.3	75%	75%		8.2	3.0
	<b>20.1</b>	<b>4.55</b>	<b>91.8</b>	<b>33.4</b>			<b>2.3</b>	<b>63.8</b>	<b>23.2</b>
<b>Prospective resource:</b>									
Angola Block 23 - Azul	12.0	5.00	60.0	21.8	50%	10%	5.0	0.0	0.0
	<b>12.0</b>		<b>60.0</b>	<b>21.8</b>			<b>5.0</b>	<b>0.0</b>	<b>0.0</b>
<b>Total</b>	<b>64.0</b>		<b>237.3</b>	<b>86.3</b>			<b>7.3</b>	<b>149.3</b>	<b>54.3</b>

Source: Cavendish estimates

Discounted at 10% to 1 January 2024.

Assumes long term Brent oil price of US\$70/bbl.

## Sonangol deal completes

Income statement		2020A	2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec	Dec
<b>Sales</b>	\$m	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>15.0</b>	<b>114.7</b>
Cost of sales	\$m	0.0	0.0	0.0	-6.7	-52.3
<b>Gross profit</b>	<b>\$m</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>8.3</b>	<b>62.5</b>
Operating expenses	\$m	-2.0	-4.7	-8.7	-7.3	-5.9
<b>EBITDA (adjusted)</b>	<b>\$m</b>	<b>-2.0</b>	<b>-4.7</b>	<b>-8.7</b>	<b>1.0</b>	<b>56.6</b>
Depreciation	\$m	-0.2	-0.2	-0.2	-2.7	-18.8
Amortisation	\$m	0.0	0.0			
<b>EBIT (adjusted)</b>	<b>\$m</b>	<b>-2.2</b>	<b>-5.0</b>	<b>-9.0</b>	<b>-1.7</b>	<b>37.8</b>
Associates/other	\$m	0.0	0.0	0.0	0.0	0.0
Net interest	\$m	0.3	-0.0	-0.1	-0.3	-4.4
<b>PBT (adjusted)</b>	<b>\$m</b>	<b>-1.9</b>	<b>-5.0</b>	<b>-9.1</b>	<b>-2.0</b>	<b>33.4</b>
<i>restructuring costs</i>	<i>\$m</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>
<i>share based payments</i>	<i>\$m</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>
<i>other adjustments</i>	<i>\$m</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>
Total adjustments	\$m	0.0	0.0	0.0	0.0	0.0
<b>PBT (stated)</b>	<b>\$m</b>	<b>-1.9</b>	<b>-5.0</b>	<b>-9.1</b>	<b>-2.0</b>	<b>33.4</b>
Tax charge	\$m	0.0	0.0	0.0	-1.0	-6.7
<i>tax rate</i>	<i>%</i>	<i>n/a</i>	<i>n/a</i>	<i>n/a</i>	<i>n/a</i>	<i>20.2</i>
Minorities	\$m	0.0	0.0	0.0	0.0	0.0
<b>Reported earnings</b>	<b>\$m</b>	<b>-1.9</b>	<b>-5.0</b>	<b>-9.1</b>	<b>-3.1</b>	<b>26.6</b>
Tax effect of adjustments / other	\$m					
<b>Adjusted earnings</b>	<b>\$m</b>	<b>-1.9</b>	<b>-5.0</b>	<b>-9.1</b>	<b>-3.1</b>	<b>26.6</b>
<i>shares in issue (year end)</i>	<i>m</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>
<i>shares in issue (weighted average)</i>	<i>m</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>
<i>shares in issue (fully diluted)</i>	<i>m</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>	<i>220.1</i>
<b>EPS (adjusted, fully diluted)</b>	<b>c</b>	<b>-0.9</b>	<b>-2.3</b>	<b>-4.1</b>	<b>-1.4</b>	<b>12.1</b>
EPS (stated)	c	-0.9	-2.3	-4.1	-1.4	12.1
<b>DPS</b>	<b>c</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>

Growth analysis (adjusted basis where applicable)						
Sales growth	%	n/m	n/m	n/m	n/m	667.5%
EBITDA growth	%	n/m	-139.4%	-84.1%	111.6%	n/m
EBIT growth	%	n/m	-129.2%	-80.1%	80.8%	n/m
PBT growth	%	n/m	-161.9%	-82.0%	77.8%	n/m
EPS growth	%	n/m	-161.9%	-82.0%	66.3%	971.3%
DPS growth	%	n/m	n/m	n/m	n/m	n/m

Profitability analysis (adjusted basis where applicable)						
Gross margin	%	n/m	n/m	n/m	55.3%	54.4%
EBITDA margin	%	n/m	n/m	n/m	6.8%	49.3%
EBIT margin	%	n/m	n/m	n/m	-11.5%	32.9%
PBT margin	%	n/m	n/m	n/m	-13.5%	29.1%
Net margin	%	n/m	n/m	n/m	-20.5%	23.2%

## Sonangol deal completes

Cash flow		2020A	2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec	Dec
EBITDA	\$m	-2.0	-4.7	-8.7	1.0	56.6
Net change in working capital	\$m	-0.2	0.2	2.0	-15.1	-2.8
Share based payments	\$m	0.0	0.0	0.0	0.0	0.0
Profit/(loss) on sale of assets	\$m	0.0	0.0			
Net pensions charge	\$m					
Change in provision	\$m					
Other items	\$m	0.0	0.0	0.0	-1.0	-6.7
<b>Cash flow from operating activities</b>	<b>\$m</b>	<b>-2.1</b>	<b>-4.5</b>	<b>-6.7</b>	<b>-15.1</b>	<b>47.1</b>
Cash interest	\$m	0.0	0.0	0.0	-0.5	-4.6
Tax paid	\$m	0.0	0.0	0.0	0.0	0.0
Capex	\$m	-0.1	-0.2	-0.2	-2.9	-36.4
Other items	\$m	0.0	0.0	0.0	0.0	0.0
<b>Free cash flow</b>	<b>\$m</b>	<b>-2.3</b>	<b>-4.7</b>	<b>-6.9</b>	<b>-18.6</b>	<b>6.0</b>
Disposals	\$m	0.0	0.0	0.0	0.0	0.0
Acquisitions	\$m	0.0	0.0	0.0	-32.7	-13.1
Dividends on ord shares	\$m	0.0	0.0	0.0	0.0	0.0
Other cashflow items	\$m	0.0	-0.3	-10.3	43.6	3.3
Issue of share capital	\$m	0.0	0.0	0.0	0.0	0.0
<b>Net change in cash flow</b>	<b>\$m</b>	<b>-2.2</b>	<b>-5.0</b>	<b>-17.2</b>	<b>-7.7</b>	<b>-3.8</b>
Opening net cash (debt)	\$m	44.9	42.7	37.7	20.4	-21.0
<b>Closing net cash (debt)</b>	<b>\$m</b>	<b>42.7</b>	<b>37.7</b>	<b>20.4</b>	<b>-21.0</b>	<b>-28.0</b>

Cash flow analysis						
Cash conversion (op cash flow / EBITDA)	%	n/m	n/m	n/m	n/m	83.1%
Cash conversion (free cash flow / EBITDA)	%	113.6%	99.3%	78.5%	n/m	10.7%
Underlying free cash flow (capex = depreciation)	\$m	-2.3	-4.7			
Cash quality (underlying FCF / adjusted earnings)	%	122.9%	95.0%			
Investment rate (capex / depn)	x	0.5	0.9	0.7	1.1	1.9
Interest cash cover	x	n/a	n/a	n/a	n/a	10.3
Dividend cash cover	x	n/a	n/a	n/a	n/a	n/m

## Sonangol deal completes

Balance sheet		2020A	2021A	2022A	2023E	2024E
Year end:		Dec	Dec	Dec	Dec	Dec
Tangible fixed assets	\$m	0.8	0.7	0.5	33.5	64.2
Goodwill	\$m	0.0	0.0	0.0	0.0	0.0
Other intangibles	\$m	21.2	21.3	21.3	21.3	21.3
Other non current assets	\$m	0.0	0.0	0.0	0.0	0.0
<i>inventories</i>	<i>\$m</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>	<i>0.0</i>
<i>trade receivables</i>	<i>\$m</i>	<i>0.2</i>	<i>0.3</i>	<i>0.4</i>	<i>10.3</i>	<i>10.3</i>
<i>trade payables</i>	<i>\$m</i>	<i>-0.2</i>	<i>-0.5</i>	<i>-2.7</i>	<i>2.5</i>	<i>2.5</i>
Net working capital	\$m	-0.0	-0.2	-2.3	12.7	12.7
Other assets	\$m	0.0	0.0	10.2	0.2	0.2
Other liabilities	\$m	-0.8	-0.6	-0.4	-0.4	-0.4
Gross cash & cash equivalents	\$m	42.7	37.7	20.4	12.6	8.9
<b>Capital employed</b>	<b>\$m</b>	<b>63.9</b>	<b>58.9</b>	<b>49.8</b>	<b>80.0</b>	<b>106.9</b>
Gross debt	\$m	0.0	0.0	0.0	33.6	36.9
Net pension liability	\$m	0.0	0.0	0.0	0.0	0.0
Shareholders equity	\$m	63.9	58.9	49.8	46.4	70.0
Minorities	\$m	0.0	0.0	0.0	0.0	0.0
<b>Capital employed</b>	<b>\$m</b>	<b>63.9</b>	<b>58.9</b>	<b>49.8</b>	<b>80.0</b>	<b>106.9</b>
<b>Leverage analysis</b>						
Net debt / equity	%	no debt	no debt	no debt	45.1%	40.0%
Net debt / EBITDA	x	n/a	n/a	n/a	20.7	0.5
Liabilities / capital employed	%	0.0%	0.0%	0.0%	42.0%	34.5%
<b>Working capital analysis</b>						
Net working capital / sales	%	n/m	n/m	n/m	85.2%	11.1%
Net working capital / sales	days	n/m	n/m	n/m	311	41
Inventory (days)	days	n/m	n/m	n/m	0	0
Receivables (days)	days	n/m	n/m	n/m	251	33
Payables (days)	days	n/m	n/m	n/m	n/a	n/a
<b>Capital efficiency &amp; intrinsic value</b>						
Adjusted return on equity	%	-3.0%	-8.5%	-18.2%	-6.6%	38.0%
RoCE (EBIT basis, pre-tax)	%	-3.4%	-8.5%	-18.0%	-2.1%	35.3%
RoCE (underlying free cash flow basis)	%	-3.7%	-8.1%			
NAV per share	c	29.0	26.8	22.6	21.1	31.8
NTA per share	c	19.4	17.1	12.9	11.4	22.1

## Sonangol deal completes

## Research

Stephen Barrett	020 7220 0552	sbarrett@cavendish.com	Michael Hill	020 7220 0554	mhill@cavendish.com
Mark Brewer	020 7220 0556	mbrewer@cavendish.com	Adam McCarter	020 7220 0553	amccarter@cavendish.com
John-Marc Bunce	020 7397 8918	jbunce@cavendish.com	James McCormack	020 7397 8915	jmccormack@cavendish.com
David Buxton	020 7220 0542	dbuxton@cavendish.com	Ian McNally	0131 220 9777	imcinaly@cavendish.com
Kimberley Carstens	020 7220 0548	kcarstens@cavendish.com	Mark Paddon	020 7220 0541	mpaddon@cavendish.com
Michael Clifton	020 3772 4682	mclifton@cavendish.com	Nigel Parson	020 7220 0544	nparson@cavendish.com
Andrew Darley	020 7220 0547	adarley@cavendish.com	Andrew Renton	020 7397 1939	arenton@cavendish.com
Chris Donnellan	020 7397 1926	cdonnellan@cavendish.com	Peter Renton	020 7397 1938	prenton@cavendish.com
Will Dymott	0131 220 9109	wdymott@cavendish.com	Edward Stacey	020 7397 1972	estacey@cavendish.com
Andrew Gibb	020 7397 1936	agibb@cavendish.com	Jonathan Wright	020 7220 0543	jwtwright@cavendish.com
Guy Hewett	020 7220 0549	ghewett@cavendish.com			

## Equity Capital Markets

Nigel Birks	020 3772 4656	nbirks@cavendish.com	Tim Redfern	020 7220 0515	tredfern@cavendish.com
Andrew Burdis	020 7220 0524	aburdis@cavendish.com	Sunila de Silva	020 7220 0521	sdesilva@cavendish.com
Charlie Combe	020 7397 1966	ccombe@cavendish.com	Charlotte Sutcliffe	020 7220 0513	csutcliffe@cavendish.com
Barney Hayward	020 7220 0518	bhayward@cavendish.com	Harriet Ward	020 7220 0512	hward@cavendish.com

## Sales

Dale Bellis	020 7397 1928	dbellis@cavendish.com	Michael Johnson	020 7397 1933	mjohnson@cavendish.com
Jasper Berry	020 7397 1941	jberry@cavendish.com	Iain Macarthur	0131 220 9776	imacarthur@cavendish.com
George Budd	020 7397 1930	gbudd@cavendish.com	Henry Nicol	020 7397 1924	hnicol@cavendish.com
Tamar Cranford-Smith	020 7397 1935	tcranfordsmith@cavendish.com	Leif Powis	020 7397 8914	lpowis@cavendish.com
Graham Hall	020 7397 8919	ghall@cavendish.com	Louise Talbot	020 3772 4651	ltalbot@cavendish.com

## Investor Relations

Julia Barnes	020 7397 1934	jbarnes@cavendish.com	Lucy Nicholls	020 7220 0528	lnicholls@cavendish.com
Anne Cassels	0131 220 9770	acassels@cavendish.com	Brittany Stevens	020 3772 4653	bstevens@cavendish.com
Malika Datta	020 7397 1925	mdatta@cavendish.com	Helen Worrall	020 3772 4652	hworrall@cavendish.com
Brittany Henderson	020 7220 0592	bhenderson@cavendish.com			

## Sales Trading

Stuart Allen	020 7397 1946	sallen@cavendish.com	Charlie Evans	020 7220 0531	cevans@cavendish.com
Gary Cunningham	020 7397 8951	gcunningham@cavendish.com	Daniel Smith	020 7220 0533	dsmith@cavendish.com

## Market Makers

Adam Crickmay	020 7397 8957	acrickmay@cavendish.com	Anthony Harmer	020 7397 1917	aharmer@cavendish.com
Andy Baker	020 7397 1916	abaker@cavendish.com	Lee Hibberd	020 7397 8954	lhibberd@cavendish.com
Jamie Dunleavy	020 7220 0534	jdunleavy@cavendish.com	Charlie Woolmer	020 7397 8955	cwoolmer@cavendish.com
James Foster	020 7397 1942	jfoster@cavendish.com	Oliver Ratcliff	020 7220 0530	oratcliff@cavendish.com

## Investment Companies

Daniel Balabanoff	020 7397 1909	dbalabanoff@cavendish.com	Oscar Valeur-Adu	020 7397 1918	ovaleuradu@cavendish.com
Lacey Beckett	020 7397 1914	lbeckett@cavendish.com	Andrew Worne	020 7397 1912	aworne@cavendish.com
Johnny Hewitson	020 7220 0558	jhewitson@cavendish.com	Justin Zawoda-Martin	020 7397 1923	jzawodamartin@cavendish.com
Pauline Tribe	020 7220 0517	ptribe@cavendish.com			

## Investment risk

Investing in shares presents risks and opportunities. The past is not necessarily a guide to the future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. The information on future performance in this communication is an illustration and is not a reliable guide to actual future performance.

## Non-UK stocks

International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk.

## Disclosures

### Analyst certification

The Sales Person(s) / Research Analyst(s) responsible for preparing this investment recommendation/report or sections of this report, in whole or in part, hereby certify/ies that, with respect to any and all of the securities or issuers that the Sales Person(s) / Research Analyst(s) cover(s) in this report, the views expressed in this report accurately reflect his/her/their personal views. However, this investment recommendation / report may have been disclosed to the issuer prior to its publication and may have been subject to amendment thereafter. The proprietary models used in production of this investment recommendation are available on request. It is intended that the proprietary models used in this investment recommendation shall be updated when appropriate. In addition, no part of the Sales Person(s) / Research Analyst(s)' compensation was, is, or will be directly or indirectly, related to the specific recommendations or view expressed in this report or summary.

### Recommendations definitions

Definition of research recommendations

Expected absolute returns

BUY is an expected return greater than 10%

HOLD is an expected return -10% - +10%

SELL is an expected return less than -10%

UNDER REVIEW: recommendation and/or forecasts are under review pending further clarity as to the company's financial and/or operational position

CORP: denotes corporate client of Cavendish Securities plc or Cavendish Capital Markets Limited

For Sales recommendation please refer to <https://www.cavendish.com>

### Distribution of investment recommendations as per 08/12/2023

	Corporate client no.	Corporate client %	Total no.	Total %
Buy	9	5.8%	21	12.0%
Hold	0	0.0%	2	1.1%
Sell	0	0.0%	0	0.0%
Under Review	0	0.0%	0	0.0%
Corp	142	91.0%	152	86.9%

Temporary movements by stocks across the boundaries of these categories due to share price volatility will not necessarily trigger a recommendation change. All recommendations are based on 12-month time horizon unless otherwise stated.

### Recommendation history

Company	Disclosures	Date	Rec	Price	Target price
Afentra		5 May 23	Buy	25.0p	37.0p

Source: Cavendish

A list of all the recommendations produced/issued by the relevant Sales Person / Research Analyst on any financial instrument or issuer disseminated during the preceding 12 months is available upon request free of charge. Please contact the appropriate Cavendish analyst or your Cavendish contact on 020 7220 0500.

### Legend

- The Sales / Research Analyst persons closely associated with them and/or persons involved in the preparation of the investment recommendation, has a beneficial interest in the shares of this issuer. This holding(s) was not received or purchased prior to a public offering of such shares.
- The Sales / Research Analyst responsible for this investment recommendation may have his/her remuneration linked to investment banking transactions performed by Cavendish.
- A director, officer or employee of Cavendish or a person closely associated to him/her, is an officer, director, or serves as an adviser or board member of the issuer. Where this person is the person responsible for this investment recommendation or a person closely associated with them, this will be indicated.
- As at the date of this investment recommendation / report, Cavendish has a beneficial interest exceeding 5% of the total issued share capital in the issuer.
- As at the date of this investment recommendation / report, the issuer has a beneficial interest exceeding 5% of the total issued share capital of Cavendish.
- Cavendish acts as a market maker or liquidity provider in relation to securities issued by the issuer.
- Cavendish has been the lead manager or co-lead manager in a public offering of the issuer's financial instruments during the previous 12 months.
- Cavendish is party to an agreement with the issuer and has received compensation from the issuer for the provision of investment banking or financial advisory services within the previous 12 months.
- Cavendish is party to an agreement with the issuer relating to the provision of investment recommendations for this issuer and Cavendish may receive remuneration for such service.
- Cavendish acts as a corporate broker to this issuer.
- Cavendish acts as a nominated adviser, financial adviser or as a sponsor to the issuer in the UK.
- As at the date of this investment recommendation, Cavendish has a net short position exceeding 0.5% of the total issued share capital of the issuer.
- As at the date of this investment recommendation, Cavendish has a net long position exceeding 0.5% of the total issued share capital of the issuer.
- Any other specific disclosures.



## Sonangol deal completes

## Disclaimer

This communication is NON-INDEPENDENT RESEARCH AND A MARKETING COMMUNICATION under the FCA's Conduct of Business Sourcebook (COBS) and is issued in the UK by Cavendish, the trading name for the business operated by Cavendish Capital Markets Limited and Cavendish Securities plc, both of which are authorised and regulated by the Financial Conduct Authority (FCA) and are members of the London Stock Exchange. Non-independent research has not been prepared in accordance with the legal requirements to promote independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Cavendish considers that this communication constitutes an acceptable minor non-monetary benefit in accordance with chapter 2.3A.19 R (5) (b) or (g) of COBS as appropriate.

This document and any investment to which this document relates is intended for the sole use of the persons to whom it is addressed and is for distribution in the United Kingdom only to 'professional clients' or 'eligible counterparties' within the meaning of chapter 3 of COBS or persons described in Articles 19(5) (Investment professionals) or 49(2) (High net worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) ('FPO') and all other exempt persons under the FPO (all such persons together being referred to as 'Relevant Persons'). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as retail clients under COBS. This document is directed only at Relevant Persons. Other persons should not act or rely on this document or any of its contents. Laws and regulations of other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. Any investment to which this document relates is available only to such persons, and other classes of person should not rely on this document.

This document has been prepared and issued by Cavendish on the basis of publicly available information, internally developed data and other sources believed to be reliable. Share price performance graphs are sourced from Morningstar, FactSet, Proquote International and Thomson Reuters Datastream. The information contained in this publication was obtained from various sources believed to be reliable, but has not been independently verified by Cavendish. Cavendish does not warrant the completeness or accuracy of such information and does not accept any liability with respect to the accuracy or completeness of such information, except to the extent required by applicable law. Any opinions, projections, forecasts or estimates in this report are those of the author only, who has acted with a high degree of expertise. They reflect only the current views of the author at the date of this report and are subject to change without notice. Cavendish has no obligation to update, modify or amend this publication or to otherwise notify a reader or recipient of this publication in the event that any matter, opinion, projection, forecast or estimate contained herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. The analysis, opinions, projections, forecasts and estimates expressed in this report were in no way affected or influenced by the issuer. The author of this publication benefits financially from the overall success of Cavendish.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information may be available on request. This report may not be reproduced for further publication without the prior written permission of Cavendish. This publication is for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase or sale of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction. The investments referred to in this publication may not be suitable for all recipients. Recipients are urged to base their investment decisions upon their own appropriate investigations that they deem necessary. Any loss or other consequence arising from the use of the material contained in this publication shall be the sole and exclusive responsibility of the investor and Cavendish accepts no liability for any such loss or consequence. In the event of any doubt about any investment, recipients should contact their own investment, legal and/or tax advisers to seek advice regarding the appropriateness of investing. Some of the investments mentioned in this publication may not be readily liquid investments. Certain transactions, including those involving futures, options, and high yield securities, give rise to substantial risk and are not suitable for all investors. Investors should be aware of the additional and special risks associated with securities and investments in emerging markets. Consequently, it may be difficult to sell or realise such investments. The past is not necessarily a guide to future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk. To the extent permitted by applicable law, neither Cavendish, nor any of its directors, officers or employees, accepts and liability whatsoever for any loss, damages, costs or prejudices whatsoever arising from the use of this publication or its contents.

Cavendish has written procedures designed to identify and manage potential conflicts of interest that arise in connection with its research business and its production. Cavendish's research analysts and other staff involved in issuing and disseminating research reports operate independently of Cavendish's Corporate Finance business. Information barriers procedures are in place between the Sales and Research Analysts and staff involved in securities trading for the account of Cavendish or its clients to ensure that inside information is handled according to applicable laws and regulations.

Cavendish may be remunerated by a company for writing research on that company, in which case, a specific disclosure will be made in the relevant research report. Each company understands and agrees that the analysis, opinions, projections, forecasts and estimates expressed in such research reports will be honest and unbiased in compliance with Cavendish's Conflicts of Interests and Research Policies and will in no way be influenced by any remuneration received by Cavendish from the company. For further details, please see Cavendish's Conflicts of Interest Policy available on our website at [www.cavendish.com](http://www.cavendish.com).

Cavendish Capital Markets Limited and Cavendish Securities plc are both incorporated and principally operate in England and Wales. Cavendish is not registered as a broker-dealer in the US and relies on the exemption in Rule 15a-6 under the Securities Exchange Act of 1934 when interacting with US persons. For the purposes of this exemption, please note that this publication should not be construed as an invitation, inducement, solicitation or intermediation for the sale, subscription or purchase of any securities or for engaging in any other transaction. Cavendish Capital Markets Limited and its assets are regulated in England and Wales by the FCA (registered number 467766) and Cavendish Securities plc and its assets are regulated in England and Wales by the FCA (registered number 416932). Accordingly, laws, regulations and remedies may differ to those available in the US.

Cavendish is not registered in any Canadian jurisdiction but operates in Canada using the International Dealer and/or Adviser exemption granted by the Ontario Securities Commission, the British Columbia Securities Commission and the AMF in Québec under section 8.18 and/or 8.26 of NI31-103. Laws, regulations and remedies may differ to those available in Canada accordingly.

This document may be distributed to wholesale clients in Australia in reliance on relief pursuant to ASIC Class Order CO 03/1099.

### For Entities and Clients in the United States

Cavendish Securities Ltd is not registered as a broker-dealer with the US Securities and Exchange Commission, and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Cavendish is not a member of the Financial Industry Regulatory Authority. It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest.

This research report is only being offered to US Institutional Investors via our US chaperoning broker Auerbach Grayson and Company and is not available to, and should not be used by, any US person or entity that is not a US Institutional Investor. Cavendish cannot and will not accept orders for the securities covered in this research report placed by any person or entity in the United States. Orders should be placed with our correspondent, Auerbach Grayson & Company at 212-557-4444.

A Major US Institutional Investor who may receive and use this report must have assets under management of more than US\$100,000,000 and is either an investment company registered with the SEC under the US Investment Company Act of 1940, a US bank or savings and loan association, business development company, small business investment company, employee benefit plan as defined in SEC Regulation D, a private business development company as defined in SEC Regulation D, an organisation described in US Internal Revenue Code Section 501(c)(3) and SEC Regulation D, a trust as defined in SEC Regulation D, or an SEC registered investment adviser or any other manager of a pooled investment vehicle.